M. Para

发表

The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan

S. Hammer, S. Yerly, A. Zolopa, 2000, Antiviral therapy.

Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333.

J. Schapiro, C. Boucher, V. DeGruttola, 2000, The Journal of infectious diseases.

Evolution of recurrent herpes simplex lesions. An immunohistologic study.

T. Merigan, R. Turner, A. Miller, 1985, The Journal of clinical investigation.

Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)

R. Shafer, J. Holden-Wiltse, M. Fischl, 2000, Antimicrobial Agents and Chemotherapy.

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Kenneth H Mayer, K. Mayer, D. Forthal, 2005, The Journal of infectious diseases.

P. Spear, M. Para, L. Goldstein, 1982, Journal of virology.

Potent neutralizing activity associated with anti-glycoprotein D specificity among monoclonal antibodies selected for binding to herpes simplex virions

P. Spear, M. Para, A. Noble, 1985, Journal of virology.

Bacteremia With Streptococcus pneumoniae: Implications for Therapy and Prevention

J. R. Parsons, S. Koletar, R. Breiman, 1996 .

Aerosols containing Legionella pneumophila generated by shower heads and hot-water faucets

M. Para, J. Plouffe, J F Plouffe, 1985, Applied and environmental microbiology.

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial

Douglas D. Richman, William G. Powderly, F. S. Rhame, 1990 .

Foscarnet for suppression of human immunodeficiency virus replication

H. Balfour, C. Fletcher, F. Rhame, 1994, Antimicrobial Agents and Chemotherapy.

A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy.

J. Karn, J. Mellors, E. Acosta, 2020, Journal of Infectious Diseases.

Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1.

T. Wrin, J. Mellors, R. Begley, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials

D. Kuritzkes, J. Mellors, R. Bosch, 2016, Journal of acquired immune deficiency syndromes.

Third-Trimester Maternal Toxicity With Nevirapine Use in Pregnancy

S. Koletar, M. Poi, M. Brady, 2005, Obstetrics and gynecology.

Psychopathology in human immunodeficiency virus infection: lifetime and current assessment.

R. Bornstein, H. Nasrallah, M. Para, 1993, Comprehensive psychiatry.

Depression and neuropsychological performance in asymptomatic HIV infection.

R. Bornstein, H. Nasrallah, M. Para, 1993, The American journal of psychiatry.

Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity

W. Sadee, S. Koletar, Danxin Wang, 2011, Pharmacogenetics and genomics.

Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients

A. Papp, S. Koletar, Danxin Wang, 2012, BMC Medical Genomics.

Amprenavir and Efavirenz Pharmacokinetics before and after the Addition of Nelfinavir, Indinavir, Ritonavir, or Saquinavir in Seronegative Individuals

K. Yarasheski, R. Reichman, S. Rosenkranz, 2005, Antimicrobial Agents and Chemotherapy.

Drug and alcohol use and neuropsychological performance in asymptomatic HIV infection.

R. Bornstein, H. Nasrallah, R. Fama, 1993, The Journal of neuropsychiatry and clinical neurosciences.

Duration of illness and neuropsychological performance in asymptomatic HIV infection.

R. Bornstein, H. Nasrallah, M. Para, 1994, The Journal of neuropsychiatry and clinical neurosciences.

Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers

K. Yarasheski, R. Reichman, S. Rosenkranz, 2008, Biopharmaceutics & drug disposition.

Quantitation of antigen-specific immune responses in human immunodeficiency virus (HIV)-infected individuals by limiting dilution analysis

C. Orosz, M. Para, C. Whitacre, 1992, Journal of Clinical Immunology.

Role of macrophage D-region antigens and T-lymphocyte differentiation antigens in induction of gamma interferon.

T. Merigan, A. Cunningham, M. Para, 1985, Journal of interferon research.

Neuropsychological performance and CD4 levels in HIV-1 asymptomatic infection.

R. Bornstein, H. Nasrallah, M. Para, 1994, Journal of Clinical and Experimental Neuropsychology.

Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.

L. Resnick, J. Timpone, J. Holden-Wiltse, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Difference in virulence of environmental isolates of Legionella pneumophila

M. Para, J. Plouffe, G. Bollin, 1985, Journal of clinical microbiology.

Sulfamethoxazole-trimethoprim treatment of guinea pigs infected with Legionella pneumophila.

M. Para, J. Plouffe, G. Bollin, 1984, The Journal of infectious diseases.

SUBTYPES OF LEGIONELLA PNEUMOPHILA SEROGROUP 1 ASSOCIATED WITH DIFFERENT ATTACK RATES

M. Para, J. Plouffe, B. Hackman, 1983, The Lancet.

Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.

D V Glidden, D. Glidden, C. Boucher, 2000, The Journal of infectious diseases.

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

M. Wulfsohn, S. Hammer, R. Schooley, 2012, PLoS medicine.

Diabetes mellitus presenting with ketoacidosis following pentamidine therapy in patients with acquired immunodeficiency syndrome.

M. Para, J. Plouffe, T. Herchline, 1991, The Journal of infection.

Location of the structural genes for glycoproteins gD and gE and for other polypeptides in the S component of herpes simplex virus type 1 DNA

P. Spear, M. Para, G. T. Lee, 1982, Journal of virology.

Drug Rash With Eosinophilia and Systemic Symptoms Syndrome and Renal Toxicity With a Nevirapine‐Containing Regimen in a Pregnant Patient With Human Immunodeficiency Virus

M. Para, P. Fan-Havard, Eric J. Knudtson, 2003, Obstetrics and gynecology.

Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.

M. Lederman, L. Novello, M. Para, 2008, The Journal of infectious diseases.

Comparison of molecular methods for subtyping patients and epidemiologically linked environmental isolates of Legionella pneumophila.

M. Blaser, V. Yu, M. Para, 1988, The Journal of infectious diseases.

The AIDS Clinical Trials Group

T. Merigan, D. Richman, P. Volberding, 1990 .

Immunoglobulin G(Fc)-binding receptors on virions of herpes simplex virus type 1 and transfer of these receptors to the cell surface by infection

P. Spear, M. Para, R. Baucke, 1980, Journal of virology.

Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268.

D. Finkelstein, M. Dohn, M. Para, 2000, Journal of acquired immune deficiency syndromes.

Successful use of ketoconazole for invasive cutaneous Trichophyton rubrum infection.

M. Para, R. Baker, 1984, Archives of internal medicine.

Cluster of Histoplasmosis Cases in Prisoners with HIV Infection

S. Koletar, M. Para, R. Fass, 1995 .

Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease

L. Kalish, S. Assmann, T. Flanigan, 2001, Annals of Internal Medicine.

Glycoprotein gE of herpes simplex virus type 1: effects of anti-gE on virion infectivity and on virus-induced fc-binding receptors

P. Spear, M. Para, R. Baucke, 1982, Journal of virology.

Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis.

K. Yarasheski, R. Reichman, S. Rosenkranz, 2007, Metabolic syndrome and related disorders.

ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy

J. Holden-Wiltse, M. Fischl, L. Demeter, 1999, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals

R. Pollard, G. Friedland, Patrick F. Smith, 2005, Clinical Pharmacokinetics.

Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.

S. Hammer, D. Katzenstein, M. Hughes, 2000, AIDS research and human retroviruses.

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

S. Hammer, D. Katzenstein, S. Liou, 2001, The New England journal of medicine.

Qualitative and quantitative PCR measures of cytomegalovirus in patients with advanced HIV infection who require transfusions.

L. Kalish, A. Collier, R. Pollard, 2001 .

Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group.

S. Hammer, D. Katzenstein, M. Hughes, 2000, AIDS Research and Human Retroviruses.

Use of Monoclonal Antibodies Against Two 75,000-Molecular-Weight Glycoproteins Specified by Herpes Simplex Virus Type 2 in Glycoprotein Identification and Gene Mapping

P. Spear, M. Weinberger, M. Para, 1983, Journal of virology.

Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.

S. Hammer, D. Katzenstein, M. Hughes, 2001, AIDS research and human retroviruses.

Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine

K. K. Lai, D. Katzenstein, M. Hirsch, 1995 .

The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption

M. Lederman, D. Kuritzkes, J. Mellors, 2015, AIDS.

Production of monoclonal antibodies to Legionella pneumophila serogroups 1 and 6

M. Para, J. Plouffe, 1983, Journal of clinical microbiology.

Plasmid profiles of clinical and environmental isolates of Legionella pneumophila serogroup 1

M. Para, J. Plouffe, W. Maher, 1983, Journal of clinical microbiology.

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption

M. Carrington, D. Kuritzkes, J. Mellors, 2017, Pathogens & immunity.

Taking Control: The Efficacy and Durability of a Peer-Led Uncertainty Management Intervention for People Recently Diagnosed With HIV

Erin D. Basinger, Lance S. Rintamaki, D. Brashers, 2017, Health communication.

HIV Sexual Risk Behavior Over 36 Months of Follow-Up in the World's First HIV Vaccine Efficacy Trial

S. Buchbinder, K. Mayer, T. Mastro, 2005, Journal of acquired immune deficiency syndromes.

No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.

R. Siliciano, J. Siliciano, R. Bosch, 2010, The Journal of infectious diseases.

Cellular immunotherapy of advanced human immunodeficiency virus type 1 infection using autologous lymph node lymphocytes: effects on chemokine production.

P. Triozzi, M. Para, L. Flancbaum, 1999, The Journal of infectious diseases.

Impact of Chemotherapy for HIV-1 Related Lymphoma on Residual Viremia and Cellular HIV-1 DNA in Patients on Suppressive Antiretroviral Therapy

J. Mellors, M. Para, A. Cillo, 2014, PloS one.

Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151.

R. Haubrich, D. Richman, C. Flexner, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Prevalence and significance of Legionella pneumophila contamination of residential hot-tap water systems.

M. Para, P. Arnow, P M Arnow, 1985, The Journal of infectious diseases.

Subtyping of Legionella pneumophila serogroup 1 isolates by monoclonal antibody and plasmid techniques

M. Para, J. Plouffe, W. Maher, 1987, Journal of clinical microbiology.

Effect of minor head injury on neuropsychological performance in asymptomatic HIV–2 infection.

M. Para, C. Whitacre, A. Podraza, 1993 .

Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults

Barbara A. Smith, G. Mitchell, J. Neidig, 2001, AIDS.

HIV and asthma, is there an association?

S. Koletar, P. Diaz, Jonathan P. Parsons, 2012, Respiratory medicine.

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

D. Kuritzkes, R. Leavitt, L. Na, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.

L. Resnick, M. Fischl, W. Powderly, 1995, The Journal of infectious diseases.

Partner-Specific Sexual Behavioral Differences Between Phase 3 HIV Vaccine Efficacy Trial Participants and Controls: Project VISION

M. Morris, S. Buchbinder, W. Whittington, 2006, Journal of acquired immune deficiency syndromes.

HIV Testing Outside of the Study Among Men Who Have Sex With Men Participating in an HIV Vaccine Efficacy Trial

Robert T. Chen, R. Wiegand, D. Gust, 2009, Journal of acquired immune deficiency syndromes.

Oral ingestion of Legionella pneumophila.

M. Para, J. Plouffe, G. Bollin, 1986, Journal of clinical & laboratory immunology.

Serum bactericidal activity against Legionella pneumophila

M. Para, J. Plouffe, K. A. Fuller, 1985, Journal of clinical microbiology.

Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary Peaks

Alan Forrest, Gene D. Morse, K. Yarasheski, 2007, Antimicrobial Agents and Chemotherapy.

StudySearch: a web-based application for posting and searching clinical research studies

M. Para, C. Reider, D. Carpenter, 2016, Journal of Investigative Medicine.

A Man with Shortness of Breath, Weight Loss, and Night Sweats

M. Para, 1989 .

Effect of Exercise on Neuropsychological Performance in Asymptomatic HIV Infection

R. Bornstein, M. Para, C. Whitacre, 1999, AIDS and Behavior.

Neuropsychological performance in asymptomatic HIV infection.

R. Bornstein, H. Nasrallah, M. Para, 1992, The Journal of neuropsychiatry and clinical neurosciences.

Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients

A. Papp, S. Koletar, Danxin Wang, 2012, BMC Medical Genomics.

Magnetic resonance imaging of white matter lesions in HIV infection.

R. Bornstein, H. Nasrallah, D. Chakeres, 1992, The Journal of neuropsychiatry and clinical neurosciences.

Neuropsychological performance in symptomatic and asymptomatic HIV infection.

R. Bornstein, H. Nasrallah, M. Para, 1993, AIDS.

Rate of CD4 decline and neuropsychological performance in HIV infection.

R. Bornstein, H. Nasrallah, M. Para, 1991, Archives of neurology.

Correlates of change in cytomegalovirus viremia in patients with advanced human immunodeficiency virus infection who require transfusion.

L. Kalish, A. Collier, M. Para, 2001, The Journal of infectious diseases.

Phase I/II Trial of the Anti-HIV Activity of Mifepristone in HIV-Infected Subjects ACTG 5200

D. Weiner, E. Daar, D. Reeds, 2010, Journal of acquired immune deficiency syndromes.

Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.

L. Resnick, J. Timpone, M. Fischl, 2000, Antiviral research.

Qualitative and Quantitative PCR Measures of Cytomegalovirus in Patients With Advanced HIV Infection Who Require Transfusions

L. Kalish, A. Collier, R. Pollard, 2001, Journal of acquired immune deficiency syndromes.

Production ofMonoclonal Antibodies toLegionella pneumophila Serogroups 1and6

M. Para, J. Plouffe, 1983 .

The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients.

M. Hughes, B. Taiwo, S. Rosenkranz, 2013, AIDS research and human retroviruses.

A phase I/II randomized, placebo-controlled trial of romidepsin in persons with HIV-1 on suppressive antiretroviral therapy to assess safety and activation of HIV-1 expression (A5315).

J. Karn, J. Mellors, E. Acosta, 2020, The Journal of infectious diseases.